CSPG4 and triple-negative breast carcinoma: Thus, NIR-PIT against multiple molecular targets, such as the combination of EGFR with HER2 for bladder cancer therapy 86, as well as a cocktail of EGFR, epithelial cell adhesion molecule (EpCAM), and chondroitin sulfate proteoglycan 4 (CSPG4) for the treatment of triple-negative breast cancer (TNBC) 49, exhibit therapeutic effects superior to NIR-PIT against a single target.